-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
ALGN delivered solid Q1 2026 results with revenues of $1.04B, up 6.2% Y/Y, above consensus, while adjusted EPS of $2.58 beat estimates by $0.29. Clear Aligner volumes rose 6.7% to 685.7k cases, with foreign exchange providing a $44.9M tailwind, though underlying constant currency growth was 2.6%. We view broad-based growth across customer segments positively, with orthodontist shipments up 7.4% and GP dentist volumes increasing 5.6%. The company is supported by a strong balance sheet with $1.06B in cash. Management reaffirmed full-year 2026 guidance for 3-4% revenue growth with mid-single digit Clear Aligner volume growth and non-GAAP operating margin of ~23.7%. Adjusted operating margin expanded 240 bps to 21.5%, reflecting restructuring benefits that should continue supporting profitability improvements. The company completed a $200M share repurchase and announced an additional $200M buyback starting May 2026, demonstrating shareholder-friendly capital allocation, in our view.